Tesla Is Trading on a $420 SpaceX Bid That No One Has Offered
No offer exists, yet Tesla holders are pricing a $420 all-stock SpaceX bid. Gary Black's live counterexample, the Marvell-Lumentum deal, turned a 24% paper premium into a 27% loss inside a week.
Vincent Jiangtwo-minute read
No offer exists, and Tesla trades as if one does
Tesla+4.53% — Tesla, up 4.53 percent today added 4.6% on Friday and SpaceX+9.50% — SpaceX, up 9.50 percent today 9.7%, and no offer sits between them 1. What exists dates to October 20, 2026, when Elon Musk told SpaceX's earnings call that merging it with Tesla would be a "good idea," disclosed special committees of independent directors at both boards, and recused himself from the talks as a "conflicted party" 2. A Tesla vote needs half of all shares outstanding, what Musk calls "quite a high hurdle" 2. No terms exist, and Tesla's December 3 annual meeting carries no merger proposal 3.
The market prices one anyway. Investor Ross Gerber floated a $420 all-stock bid after a Roadster debut that hovered on SpaceX thrusters, and Gary Black of The Future Fund pegs a fair premium at 20 to 25% 134. At Friday's close near $358, $420 leaves about 17% 5.
The premium is paid in shares, and the shares get sold
Black's warning, posted November 4: "A +24% premium can quickly go negative as the acquirer's stock is sold down" 1. On November 2, Marvell+5.82% — Marvell, up 5.82 percent today agreed to buy Lumentum+5.71% — Lumentum, up 5.71 percent today for 4.5 of its own shares per Lumentum share, a 23.9% premium to October 28 prices, with no collar and a close expected no earlier than 2028 6. By November 4 the target was down 27% and the acquirer 31% 1.
Marvell promised a 24% premium; within a week both stocks were down over 25%
The premium was paid in Marvell stock, and the market sold the stock
Data
| Value | |
|---|---|
| Premium Marvell offered | 23.9% |
| Lumentum (target) | -27% |
| Marvell (acquirer) | -31% |
Merger arbitrage funds buy the target and short the buyer, and every $1 off Marvell cuts $4.50 from the offer 5. In an all-stock deal the premium is written in the buyer's shares, and the first thing the market does with those shares is sell them.
The patient, the donor and the salesman
The bulls have a case. Barron's Al Root: "SpaceX is a much better tech stock than Tesla" 7. SpaceX's quarter backs him: revenue up 161% to $14.58 billion, AI revenue up ninefold to $7.56 billion, all on $16.4 billion of quarterly AI capital spending and $36.8 billion of mid-year debt and leases 2.
SpaceX's AI capital spending outran its quarterly revenue
Data
| Q3 2026 | |
|---|---|
| Revenue | $14.58B |
| AI revenue | $7.56B |
| AI capital spending | $16.4B |
Scott Galloway answers with anatomy: Tesla is the patient, SpaceX the organ donor 1. Mark Cuban, on The Diary of a CEO podcast, calls Musk "the best entrepreneur of our lifetimes" and "a sales guy" who has "gotta sell what he's got to sell" 8. The sell is landing: Tesla trades at 189 times forward earnings against a three-year average of 137 3.
One term sheet prints the premium, then the arbs vote
Watch the special committees' first term sheet; whatever premium it prints, the arbitrage funds cast the next vote. The Inference traced in October how Tesla's proxy already pays Musk on deal price alone.
Get Robotics & Defense by email, free
Robots, self-driving vehicles, drones and AI in defense. In our daily email, every weekday.
